CoChat

Dose response of subcutaneous GLP‐1 infusion in patients with type 2 diabetes

Torekov, S. S., Kipnes, M. S., Harley, R. E., Holst, J. J., Ehlers, M. R. · 2011 · Diabetes, Obesity and Metabolism
Cited by 25

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Aim: To evaluate the dose–response relationship of the recombinant glucagon‐like peptide‐1 (7‐36) amide (rGLP‐1) administered by continuous subcutaneous infusion (CSCI) in subjects with type 2 diabetes, with respect to reductions in fasting, postprandial and 11‐h serum glucose profiles. Methods: In a double‐blind, parallel, placebo‐controlled trial, 47 patients were randomized to placebo or rGLP‐1 (1.25, 2.5, 5.0 or 8.5 pmol/kg/min) by CSCI for 7 days. On day 1 (pretreatment) and on day 8, patients underwent monitoring of fasting, postprandial, and 11‐h profiles of glucose and hormones. Results: Fasting serum glucose decreased by 76.2, 53.9, 37.0 and 22.7 mg/dl for the 8.5, 5.0, 2.5 and 1.25 pmol/kg/min rGLP‐1 groups, respectively, compared to a decrease of 1.1 mg/dl for placebo (p = 0.0002, 0.005, 0.064 and 0.27, respectively). Mean 11‐h serum glucose area under the curve decreased by 36.3, 23.3, 16.9 and 10.0% for 8.5, 5.0, 2.5 and 1.25 pmol/kg/min rGLP‐1, respectively, compared to no change for placebo (p = 0.0001, 0.0019, 0.012 and 0.14, respectively). Mean fasting C‐peptide increased dose dependently with rGLP‐1 (p = 0.0023 for the highest dose) and decreased with placebo. There were no serious safety concerns and no instances of hypoglycaemia. Conclusions: rGLP‐1 produced continuous improvements in glycaemic control across a broad dose range of up to 8.5 pmol/kg/min.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1463-1326.2011.01388.x

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 25

Metadata

Authors
Torekov, S. S., Kipnes, M. S., Harley, R. E., Holst, J. J., & Ehlers, M. R.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2011-05-24
Volume
13
Issue
7
Pages
639-643
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2023896406
Cited by
25
References
4
FWCI
1.41
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dose response of subcutaneous GLP‐1 infusion in patients with type 2 diabetes. https://app.cochat.ai/papers/10.1111/j.1463-1326.2011.01388.x
The paper
Torekov, S. S., Kipnes, M. S., Harley, R. E., Holst, J. J., & Ehlers, M. R. (2011). Dose response of subcutaneous GLP‐1 infusion in patients with type 2 diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2011.01388.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.